Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.

Latest From Sten Stovall

Antibiotic Pioneers Increasingly Looking to Emerging Markets For Partners

Small- to medium-sized drug makers developing new products for resistant infections are increasingly partnering with players in emerging markets such as China because of the absence of workable risk/reward systems in rich countries, according to a report by The Access To Medicine Foundation.

Infectious Diseases Companies

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases

GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight

French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.

Clinical Trials Gene Therapy

Novo Nordisk's Keenly Awaited Semaglutide Trial To ‘Redefine’ Alzheimer’s?

Novo Nordisk has initiated its Phase III trial assessing its oral GLP-1 semaglutide in early Alzheimer’s disease patients. The firm’s veteran GLP-1 agonist pioneer Lotte Bjerre Knudsen explains its promise to Scrip.

Clinical Trials Companies

Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment

Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.

Brexit Clinical Trials

Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile Clinical Trials
See All
UsernamePublicRestriction

Register